Research Analysts Set Expectations for VKTX FY2026 Earnings

Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Viking Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse anticipates that the biotechnology company will earn ($4.01) per share for the year. Cantor Fitzgerald currently has a "Strong-Buy" rating on the stock. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The biotechnology company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.10). The firm's revenue was up .0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) EPS.

Several other research firms also recently commented on VKTX. HC Wainwright reissued a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a research report on Thursday, April 24th. Truist Financial reiterated a "buy" rating and set a $75.00 target price (down from $95.00) on shares of Viking Therapeutics in a research note on Monday, April 28th. The Goldman Sachs Group started coverage on Viking Therapeutics in a research note on Tuesday, April 8th. They issued a "neutral" rating and a $30.00 target price for the company. Morgan Stanley decreased their price target on Viking Therapeutics from $105.00 to $102.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Finally, Scotiabank initiated coverage on Viking Therapeutics in a research report on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $87.15.

Viking Therapeutics Stock Performance

Shares of NASDAQ:VKTX traded down $0.37 during midday trading on Wednesday, hitting $28.58. 2,469,807 shares of the stock were exchanged, compared to its average volume of 4,054,560. The company has a market capitalization of $3.21 billion, a PE ratio of -28.58 and a beta of 0.65. Viking Therapeutics has a 52-week low of $18.92 and a 52-week high of $81.73. The business's fifty day simple moving average is $26.34 and its two-hundred day simple moving average is $32.37.

Insider Buying and Selling

In other Viking Therapeutics news, Director Sarah Kathryn Rouan purchased 1,240 shares of the stock in a transaction on Monday, March 31st. The stock was bought at an average cost of $24.15 per share, for a total transaction of $29,946.00. Following the completion of the acquisition, the director now directly owns 1,240 shares of the company's stock, valued at $29,946. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 4.10% of the stock is owned by insiders.

Institutional Trading of Viking Therapeutics

A number of institutional investors have recently modified their holdings of VKTX. Virtu Financial LLC acquired a new position in shares of Viking Therapeutics during the 4th quarter worth about $1,715,000. Mirae Asset Global Investments Co. Ltd. bought a new position in Viking Therapeutics during the fourth quarter worth about $528,000. Van ECK Associates Corp boosted its stake in shares of Viking Therapeutics by 58.0% in the fourth quarter. Van ECK Associates Corp now owns 14,911 shares of the biotechnology company's stock valued at $600,000 after buying an additional 5,475 shares during the period. Blue Trust Inc. increased its position in shares of Viking Therapeutics by 363.1% in the fourth quarter. Blue Trust Inc. now owns 1,885 shares of the biotechnology company's stock worth $76,000 after purchasing an additional 1,478 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of Viking Therapeutics in the 4th quarter valued at approximately $429,000. 76.03% of the stock is currently owned by institutional investors.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.